Menu Search
Equities

Novo Nordisk A/S

NOVX:GER

Novo Nordisk A/S

Actions
  • Price (EUR)101.00
  • Today's Change3.39 / 3.47%
  • Shares traded82.32k
  • 1 Year change+6.97%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in DKKIncome statement in DKKView more

Year on year Novo Nordisk A/S grew revenues 31.26% from 176.95bn to 232.26bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 50.71% net income growth from 55.53bn to 83.68bn.
Gross margin84.66%
Net profit margin35.01%
Operating margin43.75%
Return on assets27.16%
Return on equity88.73%
Return on investment59.83%
More ▼

Cash flow in DKKView more

In 2023, Novo Nordisk A/S increased its cash reserves by 13.74%, or 1.74bn. The company earned 108.91bn from its operations for a Cash Flow Margin of 46.89%. In addition the company used 43.89bn on investing activities and also paid 63.16bn in financing cash flows.
Cash flow per share23.23
Price/Cash flow per share24.53
Book value per share27.29
Tangible book value per share14.95
More ▼

Balance sheet in DKKView more

Novo Nordisk A/S has a Debt to Total Capital ratio of 32.10%, a higher figure than the previous year's 21.43%.
Current ratio0.9367
Quick ratio0.7546
Total debt/total equity0.4727
Total debt/total capital0.321
More ▼

Growth rates in DKK

SmartText is unavailable
Div yield(5 year avg)1.52%
Div growth rate (5 year)18.20%
Payout ratio (TTM)44.33%
EPS growth(5 years)18.50
EPS (TTM) vs
TTM 1 year ago		27.24
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.